RRC ID |
30914
|
著者 |
Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.
|
タイトル |
YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
|
ジャーナル |
Int J Cancer
|
Abstract |
Because available treatments have limited efficacy in triple-negative breast cancer (TNBC), the identification of new therapeutic strategies to improve patients' outcome is urgently needed. In our study, we investigated the effects of the administration of the small molecule selective survivin suppressant YM155, alone or in association with CD34+ cells transduced with a replication-deficient adenovirus encoding the human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene (CD34-TRAIL+ cells), in three TNBC cell models. YM155 exposure significantly impaired TNBC cell growth and selectively modulated survivin expression at both mRNA and protein level. In addition, co-culturing YM155-treated TNBC cells with CD34-TRAIL+ cells resulted in markedly increased cytotoxic effect and apoptotic response in comparison with single treatments. Such a chemosensitizing effect was observed only in TNBC cells inherently expressing DR5 and relied on the ability of YM155 to upregulate DR5 expression through a p38 MAPK- and CHOP-dependent mechanism. YM155/CD34-TRAIL+ combination also showed a significant inhibitory effect on the growth of DR5-expressing TNBC cells following xenotransplantation into NOD/SCID mice, in the absence of toxicity. Overall, our data (i) provide, for the first time, evidence that YM155 sensitizes TNBC cells to CD34-TRAIL+ cells-induced apoptosis by a mechanism involving the downregulation of survivin and the simultaneous p38 MAPK- and CHOP-mediated upregulation of DR5, and (ii) suggest the combination of YM155 with TRAIL-armed CD34+ progenitor cells as a promising therapeutic option for patients with TNBC expressing DR5.
|
巻・号 |
136(2)
|
ページ |
299-309
|
公開日 |
2015-1-15
|
DOI |
10.1002/ijc.28993
|
PMID |
24866585
|
MeSH |
Animals
Apoptosis / drug effects
Blotting, Western
Cell Membrane / metabolism
Cell Proliferation / drug effects
Female
Flow Cytometry
Gene Expression Regulation, Neoplastic / drug effects
Humans
Imidazoles / pharmacology*
Inhibitor of Apoptosis Proteins / antagonists & inhibitors
Inhibitor of Apoptosis Proteins / metabolism
Mice
Mice, Inbred NOD
Mice, SCID
Naphthoquinones / pharmacology*
Reactive Oxygen Species / metabolism
Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism*
Survivin
TNF-Related Apoptosis-Inducing Ligand / metabolism*
Transcription Factor CHOP / metabolism*
Triple Negative Breast Neoplasms / drug therapy*
Triple Negative Breast Neoplasms / metabolism*
Triple Negative Breast Neoplasms / pathology
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
p38 Mitogen-Activated Protein Kinases / metabolism*
|
IF |
5.145
|
引用数 |
20
|
WOS 分野
|
ONCOLOGY
|
リソース情報 |
遺伝子材料 |
hTRAIL/pMKITneo (RDB02934) |